GlaxoSmithKline Pharmaceuticals Limited vs Pfizer Limited
An objective side-by-side of GLAXO and PFIZER, both in Pharmaceuticals - Multinational: valuation, profitability, growth, balance sheet, ownership and share-price performance. Where one number is clearly better on its own terms (lower P/E, higher ROE), it is shaded. That is a description, not a recommendation.
Prices as of 2026-09-21 close
Latest results: GLAXO Jun 2026 · PFIZER Mar 2026
At a glance
- GlaxoSmithKline Pharmaceuticals Limited is the larger company by market value, about 2.6 times the size of Pfizer Limited.
- On trailing earnings, Pfizer Limited trades at the lower P/E (25.5 against 45.4).
- GlaxoSmithKline Pharmaceuticals Limited earns the higher return on equity (47.1% against 17.2%).
- Over three years GlaxoSmithKline Pharmaceuticals Limited has grown profits faster (18% a year against 8%).
- Over the past year the share prices returned +3.9% (GLAXO) and -21.8% (PFIZER).
| Metric | GlaxoSmithKline Pharmaceuticals GLAXO |
Pfizer PFIZER |
|---|---|---|
| Size and price | ||
| Market cap | ₹48,499 Cr | ₹18,462 Cr |
| Share price | ₹2,863 | ₹4,036 |
| Valuation | ||
| P/E | 45.42 | 25.54 |
| P/B | 21.39 | 4.39 |
| EV/EBITDA | 30.08 | 20.50 |
| PEG | 2.52 | 3.19 |
| Dividend yield | 2.0% | 1.9% |
| Profitability | ||
| ROE | 47.1% | 17.2% |
| ROCE | 61.0% | 24.0% |
| Operating margin | 40.8% | 35.9% |
| Sales (TTM) | ₹3,955 Cr | ₹2,519 Cr |
| Net profit (TTM) | ₹1,068 Cr | ₹723 Cr |
| Growth | ||
| Latest quarter sales YoY | +16.6% | +6.2% |
| Latest quarter profit YoY | +15.7% | -39.6% |
| Sales CAGR 3Y | +6.0% | +1.0% |
| Profit CAGR 3Y | +18.0% | +8.0% |
| Sales CAGR 5Y | +5.0% | +2.0% |
| Profit CAGR 5Y | +15.0% | +9.0% |
| Financial strength | ||
| Debt/Equity | 0.01 | 0.02 |
| Interest cover | 420.19 | 94.11 |
| Ownership | ||
| Promoter holding | 75.0% | 63.9% |
| Promoter change (4 qtrs) | +0.00 pp | +0.00 pp |
| Price performance | ||
| Return 1M | -4.56% | -17.97% |
| Return 3M | +21.15% | -9.58% |
| Return 1Y | +3.91% | -21.83% |
| Return YTD | +15.74% | -19.09% |
| Technical condition | ||
| Technical score | 55 | 14 |
| RS rating (1-99) | 71.00 | 24.00 |
| % vs 200-DMA | +14.50% | -14.95% |
| RSI (14) | 51.54 | 21.09 |
| % from 52-week high | -8.26% | -27.66% |
